别嘌醇对慢性肾脏病进展的影响
这项随机对照试验纳入369例3或4期慢性肾脏病且无痛风史的高进展风险成人,比较别嘌醇(每日100–300 mg)与安慰剂的疗效。主要结局为随机化至第104周eGFR变化,结果显示两组eGFR下降速率无显著差异,别嘌醇未能延缓eGFR下降。
要点
- 在高进展风险的3–4期慢性肾脏病患者中,别嘌醇未减缓eGFR下降。
- 别嘌醇组与安慰剂组eGFR年变化差异无统计学意义(P=0.85)。
- 两组严重不良事件发生率相近(46% vs 44%)。
核心结论
- 在慢性肾脏病且进展风险高的患者中,别嘌醇降尿酸治疗与安慰剂相比未减缓eGFR下降。
研究设计与样本
- 随机、对照试验,计划纳入620例,实际随机分配369例成人3或4期慢性肾脏病且无痛风史患者。
- 入组条件为尿白蛋白与肌酐比值≥265(白蛋白mg、肌酐g)或前一年eGFR下降至少3.0 ml/min/1.73 m²。
- 干预为别嘌醇每日100–300 mg或安慰剂,主要结局为随机化至第104周eGFR变化。
主要发现
- 别嘌醇组eGFR年变化为-3.33 ml/min/1.73 m²(95%CI -4.11至-2.55),安慰剂组为-3.23 ml/min/1.73 m²(95%CI -3.98至-2.47)。
- 两组平均差异为-0.10 ml/min/1.73 m²/年(95%CI -1.18至0.97),P=0.85。
- 别嘌醇组182例中84例(46%)报告严重不良事件,安慰剂组181例中79例(44%)。
- 纳入主要结局分析的363例患者平均eGFR为31.7 ml/min/1.73 m²,中位尿白蛋白与肌酐比值为716.9,平均血尿酸为8.2 mg/dl。
临床怎么用
- 对于3–4期慢性肾脏病且高进展风险但无痛风史的患者,不应期待别嘌醇能延缓肾功能下降。
局限性
- 因招募缓慢,实际随机分配369例而非计划的620例,提前停止入组。
- 每组各有3例在随机化后立即退出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated serum urate levels are associated with progression of chronic kidney disease. Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known. METHODS: In this randomized, controlled trial, we randomly assigned adults with stage 3 or 4 chronic kidney disease and no history of gout who had a urinary albumin:creatinine ratio of 265 or higher (with albumin measured in milligrams and creatinine in grams) or an eGFR decrease of at least 3.0 ml per minute per 1.73 m2 of body-surface area in the preceding year to receive allopurinol (100 to 300 mg daily) or placebo. The primary outcome was the change in eGFR from randomization to week 104, calculated with the Chronic Kidney Disease Epidemiology Collaboration creatinine equation. RESULTS: Enrollment was stopped because of slow recruitment after 369 of 620 intended patients were randomly assigned to receive allopurinol (185 patients) or placebo (184 patients). Three patients per group withdrew immediately after randomization. The remaining 363 patients (mean eGFR, 31.7 ml per minute per 1.73 m2; median urine albumin:creatinine ratio, 716.9; mean serum urate level, 8.2 mg per deciliter) were included in the assessment of the primary outcome. The change in eGFR did not differ significantly between the allopurinol group and the placebo group (-3.33 ml per minute per 1.73 m2 per year [95% confidence interval {CI}, -4.11 to -2.55] and -3.23 ml per minute per 1.73 m2 per year [95% CI, -3.98 to -2.47], respectively; mean difference, -0.10 ml per minute per 1.73 m2 per year [95% CI, -1.18 to 0.97]; P = 0.85). Serious adverse events were reported in 84 of 182 patients (46%) in the allopurinol group and in 79 of 181 patients (44%) in the placebo group. CONCLUSIONS: In patients with chronic kidney disease and a high risk of progression, urate-lowering treatment with allopurinol did not slow the decline in eGFR as compared with placebo. (Funded by the National Health and Medical Research Council of Australia and the Health Research Council of New Zealand; CKD-FIX Australian New Zealand Clinical Trials Registry number, ACTRN12611000791932.).
引用
- Badve SV, Pascoe EM, Tiku A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020. PMID: 32579811. doi:10.1056/NEJMoa1915833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。